You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Cardiff Oncology Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Cardiff Oncology Company Info
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
News & Analysis
These clinical-stage biotech stocks are headed in opposite directions today.
Cardiff Oncology is a prime takeover target heading into 2022.
The clinical-stage oncology specialist is getting an infusion of cash from pharmaceutical giant Pfizer.
An insider buy and positive data may have boosted optimism.
This cancer specialist is looking to defeat the KRAS mutation.
The biotech presented data from an early-stage study of its experimental colorectal cancer drug.
Here's why shares of these drugmakers seem unstoppable this year.
An analyst's bullish outlook sent the biotech stock soaring.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.